Tumor Biology

, Volume 37, Issue 7, pp 8709–8714 | Cite as

A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer

Original Article

Abstract

The study was designed to test whether circulating autoantibodies against associated antigens (TAAs) were altered in early cervical cancer and benign cervical tumors. A total of 111 cervical cancer patients, 137 cervical benign tumor patients, and 160 healthy volunteers matched in age were recruited in this study. The expression of autoantibodies was tested using in-house developed enzyme-linked immunosorbent assay (ELISA) with linear peptide envelope antigens derived from TAAs. One-way ANOVA test showed that there was no difference in the CD25 autoantibody expression among the cervical cancer group, benign tumor group, and healthy control group (P = 0.063; P = 0.191). The expression of autoantibodies against survivin and TP53 in the cervical cancer group was significantly higher than that in the benign tumor group (P < 0.001; P < 0.001). The levels of autoantibodies against cyclinB-1 and ANXA-1 were higher in the cervical cancer group than in the healthy control group (P = 0.010; P = 0.001), while autoantibodies in the cervical cancer group showed no difference in expression compared with that in the benign tumor group. The panel of five TAAs showed a sensitivity of 37.8 % and a specificity of 90 %, which was much higher than the sensitivity of the single-TAA testing group. The data from this study further support our previous hypothesis that the detection of autoantibodies for the diagnosis of a specific cancer type can be enhanced using a panel of several selected TAAs as target antigens.

Keywords

Autoantibody Biomarker Early prognostic Cervical cancer 

Notes

Acknowledgments

This study was supported by the Jilin Pharmaceutical Industry Development Special Fund Project (No. 130701YY01066802), and by Glory Biomedical Co. Ltd., Taipei, Taiwan. We would like to acknowledge Dr. Cui Manhua and colleagues for their help and support with serum sample processing.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–40.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic cancer biomarkers—a review. Cancer Epidemiol Biomarkers Prev. 2013;22:2161–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y, et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci. 2012;16:2044–50.PubMedGoogle Scholar
  5. 5.
    Barrett KL, Demiranda D, Katula KS. CycinB1 promoter activity and functional in G1 phase of human breast cancer cells. J Cell Biol Int. 2002;26:19–28.CrossRefGoogle Scholar
  6. 6.
    Prystowsky M, Feeney K, Kawachi N, Montagna C, Willmott M, Wasson C, et al. Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G2 delay and mitotic defects. Sci Rep. 2013;3:2640. doi: 10.1038/srep02640.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107(14):6340–5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, et al. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis. 2008;25:695–702.CrossRefPubMedGoogle Scholar
  9. 9.
    Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, et al. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008;16:530–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Protrka Z, Arsenijevic S, Dimitrijevic A, Mitrovic S, Stankovic V, Milosavljevic M, et al. Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions. Eur J Histochem. 2011;55(1):44–9.CrossRefGoogle Scholar
  11. 11.
    Samir R, Asplund A, Tot T, Pekar G, Hellberg D. High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. J Low Genit Tract Dis. 2011;15:280–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Tornesello ML, Buonaguro L, Buonaguro FM. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol. 2013;128:442–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen ZF, Xu Q, Ding JB, Zhang Y, Du R, Ding Y. CD4+CD25+Foxp3+ Treg and TGF-beta play important roles in pathogenesis of Uygur cervical carcinoma. Eur J Gynaecol Oncol. 2012;33:502–7.PubMedGoogle Scholar
  14. 14.
    Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol. 2012;138:1737–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Cheng Y, Xu J, Guo J, Jin Y, Wang X, Zhang Q, et al. Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma. Clin Transl Oncol. 2013;15:398–402.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang C, Ye L, Guan S, Jin S, Wang W, Sun S, et al. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumour Biol. 2014;35:2047–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Jin Y, Guan S, Liu L, Sun S, Lee KH, Wei J. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asia Pac J Clin Oncol. 2014. doi: 10.1111/ajco.12198.PubMedGoogle Scholar
  18. 18.
    Wang W, Guan S, Sun S, Jin Y, Lee KH, Chen Y, et al. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Tumor Biol. 2014;35:4901–5.CrossRefGoogle Scholar
  19. 19.
    Ye L, Guan S, Zhang C, Lee KH, Sun S, Wei J, et al. Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol. 2013;34:1873–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36–45.CrossRefPubMedGoogle Scholar
  21. 21.
    Macdonald IK, Murray A, Healey GF, Parsy-Kowalska CB, Allen J, McElveen J, et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test. PLoS One. 2012;7(12):e51002. doi: 10.1371/journal.pone.0051002.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Liu W, De La Torre IG, Gutiérrez-Rivera MC, Wang B, Liu Y, Dai L, et al. Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Tumour Biol. 2015;36(2):1307–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Cao XQ, Lu HS, Zhang L, Chen LL, Gan MF. MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac J Cancer Prev. 2014;15:5271–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Sukpan K, Settakorn J, Khunamornpong S, Cheewakriangkrai C, Srisomboon J, Siriaunkgul S. Expression of survivin, CD117, and C-erbB-2 in neuroendocrine carcinoma of the uterine cervix. Int J Gynecol Cancer. 2011;21:911–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Hoffmann TK, Trellakis S, Okulicz K, Schuler P, Greve J, Arnolds J, et al. Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck. Anticancer Res. 2011;31(10):3151–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008;216:131–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Shi J, Zhou J. Role of CD4+ CD25+ regulatory T cells in peripheral blood from patients with papillary thyroid carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26(21):965–9. 972.(Article in Chinese).PubMedGoogle Scholar
  28. 28.
    Gu Y, Wang C, Han D, Zhang L. Increased frequencies of CD4+ CD25+ FOXP3+ regulatory T cells in human nasal inverted papilloma. Head Neck. 2011;33:1005–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics. 2007;6:1115–22.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of RadiotherapySecond Hospital of Jilin UniversityChangchunChina
  2. 2.Ministry of Health Key Laboratory of RadiobiologyJilin UniversityChangchunChina
  3. 3.Department of RadiotherapyTumor Hospital of Jilin ProvinceChangchunChina
  4. 4.Pei-Ling Guan-Si HospitalHsinchu CountyTaiwan

Personalised recommendations